

## Plutavimab

---

|           |                                                                                           |
|-----------|-------------------------------------------------------------------------------------------|
| Cat. No.: | HY-P99104                                                                                 |
| CAS No.:  | 2529854-88-2                                                                              |
| Target:   | SARS-CoV                                                                                  |
| Pathway:  | Anti-infection                                                                            |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |                                                                                                                                                          |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Description</b> | Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) <sup>[1]</sup><br><sup>[2]</sup> . |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

### REFERENCES

[1]. Williams, et al. Engineering of antibodies to coronavirus SARS-CoV-2 for diagnosis and treatment. World Intellectual Property Organization, WO2023070051 A1. 2023-04-27.

[2]. Plutavimab. IMGT/mAb-DB.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA